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Abstract
Adeno-associated virus (AAV) vectors represent promising candidates for gene therapy;
however, pre-existing neutralizing antibodies (NAb) may reduce AAV vector delivery effi-
ciency. In this study, the presence of AAV NAb was investigated in cats, which serve as a
larger and outbred animal model for the prediction of gene therapy outcomes in humans but
also in cats.Serum/plasma samples from 230 client-owned Swiss cats and 20 specified
pathogen-free cats were investigated for NAb to AAV1, AAV2, AAV5, AAV6, AAV7, AAV8
and AAV9 using in vitro transduction inhibition and a beta-galactosidase assay. NAb to all
tested AAV serotypes were found. Of the client-owned cats, 53% had NAb to one or more of
the AAV serotypes. NAb (�1:10) were found at frequencies of 5% (AAV6) to 28% (AAV7).
The highest titers were found against AAV7 (�1:160). The NAb prevalence to AAV2, AAV7
and AAV9 differed geographically. Regarding titers�1:10 against single AAV serotypes,
age, breed and sex of the cats were not associated with the NAb prevalence. Cats with titers
�1:20 against AAV2 and titers�1:40 against AAV7 were significantly younger than cats
with low/no titers, and purebred cats were significantly more likely than non-purebred cats to
have NAb to AAV2 (�1:40). Additionally, regarding NAb to all AAV combined, female cats
were significantly more likely than male cats to have NAb titers�1:40. Preliminary data
using AAV-DJ indicated that less pre-existing NAb to the hybrid AAV-DJ can be expected
compared to the wild-type AAV serotypes. AAV NAb will need to be taken into account for
future in vivo gene therapy studies in cats.
Introduction
Treatment of many genetic and acquired diseases remains a challenge. At present, curative
treatments are often nonexistent, inefficient or toxic [1, 2]. Thus, new classes of therapeutics
are being developed; these development efforts include the investigation and application of
gene therapy. Adeno-associated virus (AAV)-based vectors represent promising candidates
for therapeutic gene transfer due to the assumed lack of involvement in human diseases and
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their display of relatively low immunogenicity [3]. AAV has been used as a vector for over 20
years [4] in more than 100 clinical trials. Several of these trials show great promise, such as
gene therapy for hemophilia B [5, 6], Leber’s congenital amaurosis [7, 8] and Parkinson’s dis-
ease [9]. Few AAV-vector-mediated gene therapies have already been approved in Europe
including Alipogene Tiparvovec, a treatment of lipoprotein lipase deficiency as well as Lux-
turna a one-time gene therapy for the treatment of an inherited retinal dystrophy [10, 11].
With clinical assessment, however, some of the limitations of in vivo gene therapy have
emerged. Both the safety and the efficacy of gene transfer in vivo using AAV vectors are
affected by the host immune system [12]. Capsid-specific T-cell responses directed against
transduced cells might limit the duration of transgene expression following AAV gene transfer
[12]. In addition, previous infections with natural AAVs, which may have similar or even iden-
tical capsids, can result in the production of cross-reactive or specific anti-AAV neutralizing
antibodies (NAb), which partially or even completely block transduction of the target tissue [5,
13, 14]. Thus, NAb directed against AAVs have a profound impact on transduction efficiency
when the vector is delivered directly into the bloodstream or in any body compartment where
immunoglobulin can be found [12]. In the last 50 years, numerous studies have investigated
the seroprevalence of NAb directed against AAVs in the human population [15]. In humans,
the presence of pre-existing neutralizing factors for AAV is generally high and varies geo-
graphically. By the age of two years, humans have already developed antibodies against differ-
ent AAV virus capsids [16]. NAb prevalence can reach>70% for the serotype AAV2, which is
the most prevalent serotype [15, 17, 18]. In comparison, NAb against AAV5, AAV6, AAV8,
and AAV9 are significantly less prevalent, ranging from 15–47% of the population. However,
methods to investigate NAb are difficult to standardize; thus, variations in prevalence among
studies are inevitable [15, 18].
Animal studies and clinical trials have shown that low existing titers of NAb can hamper
successful transduction and therefore negatively influence the outcome of gene therapy [13,
14, 19]. In addition, due to high sequence conservation, anti-AAV antibodies show a high
degree of cross-reactivity across a wide range of serotypes. Strategies to overcome this humoral
immunity to AAV are versatile, including selection of naïve subjects, using AAV serotypes
with low seroprevalence, novel nonhuman primate AAV vectors and engineered chimeric
AAVs, higher vector doses, transient immunosuppression, empty “decoy” capsids, and com-
partmentalized delivery [12, 14, 15, 20].
For the prediction of gene therapy outcomes in humans, accurate animal models are
needed. Mouse models are commonly used and yield impressive results with efficient long-
term transgene expression and low toxicity [21, 22]. However, when gene therapy is translated
to larger animal models, such as cynomolgus macaques, the results are not as encouraging:
transduction efficiencies are reduced and toxicity due to T-cell responses observed [23]. In
addition, studies with non-human primates in general are controversial. Thus, other preclini-
cal animal models are needed, preferentially without the complexity of nonhuman primate
models. A potential candidate might be a cat model. In contrast to the laboratory mouse, the
cat is an outbred animal with a long lifespan. Cats have already been used as animal models for
several human diseases, such as Alzheimer’s disease [24], hereditary retinal blindness [25],
cancer [26] and AIDS [27].
The prevalence of certain monogenic disorders within dog and cat breeds is substantial,
probably driven by inbreeding and selection of desired characteristics. Gene therapy has
already been successfully applied in cats for lysosomal storage disorders [28] such as the
Sandhoff disease [29] or Mucopolysaccharidosis Type VI (MPS VI) [30]. Although treatment
using gene therapy has not been used widely to cats, its potential for applications, such as the
treatment of monogenic diseases in domestic cats, is tremendous.
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Thus, by surveying pre-existing NAb to AAV in domestic cats, we laid a foundation for
future studies leading towards gene therapy in this outbred species. Pre-existing neutralizing
antibodies against AAV were assessed in 250 feline samples using an in vitro transduction inhi-
bition assay. In addition, background information from the client-owned cats was analyzed in
relation to the presence of NAb.
Materials and methods
Sample collection from client-owned and specified pathogen-free (SPF)
domestic cats
In order to obtain an overview of the presence and geographic distribution of AAV NAb in
cats, sera or heparin plasma samples from client-owned cats from all over Switzerland were
used. From each of the 23 cantons, 10 samples were available, which resulted in 230 samples
representing all of Switzerland (of note, the six half-cantons were combined into 3 full can-
tons). Serum or heparin plasma samples from client-owned cats were residual samples con-
tributed by the diagnostic laboratories of the Vetsuisse Faculties in Zurich (Clinical
Laboratory, 83 samples) and Bern (Zentrallabor, 59 samples), three commercial veterinary
diagnostic laboratories (IDEXX Diavet Labor AG, Ba¨ch, Switzerland, 13 samples; Labor Zen-
tral, Geuensee, Switzerland, 11 samples and Labor am Zugersee, Switzerland, 12 samples), and
various private practices in Switzerland. All samples had been obtained solely for routine diag-
nostic purposes during clinical presentation of the cats to the veterinarians; no additional vol-
ume was collected from any of the client-owned cats for the present study. The sole inclusion
criteria were the geographic origin of the cat (area code, canton of Switzerland) and a sufficient
volume of the residual sample. If available, demographic data (age, sex, reproductive status,
breed of the cat) were included in the study. In addition, samples from 20 castrated male SPF
cats were included. The cats originated from an approved SPF cat breeding facility and were
kept in groups under optimal ethological and hygienic conditions in a barrier facility at the
University of Zurich, as previously described [31]. All 20 SPF cats involved in this study were
in unrelated experimental studies officially approved by the veterinary office of the Swiss Can-
ton of Zurich (11/2011, 160/2010 and 251/2013) and conducted in accordance with Swiss laws.
No additional blood collections were necessary for the present study; only residual samples
were used. The ages of the SPF cats ranged from 5 months to 18 years (median age = 9.5
years).
All cat serum or plasma samples were kept in long-term storage at -80˚C. Inactivated sam-
ples and dilutions were stored at -20˚C for later NAb analysis.
Cell culture
Human hepatoma cells (Huh7) or human embryonic kidney cells (HEK-293T cells) were culti-
vated in Advanced RPMI 1640 medium (12633012, Thermo Fisher Scientific, Fremont, USA)
containing 10% fetal calf serum (FCS; 16000044, Thermo Fisher Scientific), 1% (V/V) penicil-
lin/streptomycin (10378016, Thermo Fisher Scientific) and 2% (V/V) L-glutamine (25030081,
Thermo Fisher Scientific) at 37˚C in a humidified 5% CO2 incubator.
AAV vectors
In the present study, AAV1, AAV2, AAV5, AAV6, AAV7, AAV8 and AAV9 vectors were
used. All AAV (AAV.CMV.LacZ) vectors contained the reporter gene beta-galactosidase
(LacZ), driven by a cytomegalovirus (CMV) promoter. All AAV (LacZ) vectors were
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constructed, purified and quantified by the Penn Vector Core at the University of Pennsylva-
nia, as described [17].
NAb assay
In the present study, NAb against seven different AAV serotypes were investigated by using an
in vitro transduction inhibition assay.
The NAb assays were initially performed according to Calcedo and colleagues [17] using
the Huh7 cell line, when we realized that not all AAV serotypes perform optimal within the
Huh7 cells. We aimed for a low multiplicity of infection (MOI) to maximize the sensitivity of
the assay. Thus, for those AAV serotypes, where the MOIs turned out to be>10’000 with the
Huh7 cell line, we decided to do the assay with HEK-293T cells [32, 33]. Subsequently, the
Huh7 cell line was used for the AAV serotypes AAV1, AAV2 and AAV6, whereas the HEK-
293T cell line was used for the serotypes AAV5, AAV7, AAV8 and AAV9. The MOIs finally
used were all in the range of 2,000–10,000 genome copy (GC)/cell with the exception of the
MOI for AAV5, which was higher, namely, 20,000 GC/cell (Table 1). Several samples were
compared using both Huh7 and HEK-293T cell lines and identical or similar (+/- one dilution)
titers were found. This is in accordance with a paper from Wang and colleagues, where NAb
titers were compared across 7 different cell lines without any significant difference [34]. The
serum samples used in the present study were limited in volume. Therefore, not all samples
could be run using the same cell line.
The NAb assays were performed as described by Calcedo and colleagues [17] with few mod-
ifications. In brief, cells (Huh7 or HEK-293T) were passaged at a seeding rate of 5 × 104 cells
per well into 96-well plates, which were precoated with 100 μg/ml poly-D-lysine (A-003-E,
Merck KGaA, Darmstadt, Germany) for HEK-293T cells, and the cells were incubated for 24
hours. Then, the cells were infected with wild-type human adenovirus 5 (HAdV5, ATCC-VR-
1516, LGC Standards GmbH, Wesel, Germany) with an MOI of 50 particles per cell, and incu-
bated for 2 hours. Cat serum or plasma samples were heat inactivated at 56˚C for 35 minutes
before being diluted with Advanced RPMI 1640 to final concentrations of 1:10 and 1:20.
Diluted serum/plasma (100 μl) was mixed with AAV at different MOIs, dependent on the
AAV serotype (Table 1), and incubated at 37˚C for 1 hour. HAdV5 supernatants were
removed, and AAV/cat serum mixtures were added to the cells. One hour later, 100 μl of
Advanced RPMI 1640 containing 20% FCS was added to each well and incubated for 18 to 22
hours at 37˚C. As controls, wells with AAV NAb-positive human serum, a non-serum control
and a mock-infection (blank) were included during the transduction inhibition assay.
After cultivation, the cells were developed with beta-galactosidase (75710, Thermo Fisher
Scientific) resulting in a colorimetric reaction. The supernatants were removed, and the cells
were washed once with 200 μl of PBS (phosphate-buffered saline). Beta-galactosidase reagent
Table 1. List of AAV vectors, multiplicity of infection (MOI) values and cell lines used for the transduction inhibi-
tion assay.
rAAV vector MOI (GC/cell) Cell line
AAV1.CMV.LacZ.bGH 10,000 Huh7
AAV2.CMV.LacZ.bGH 2,000 Huh7
AAV5.CMV.LacZ.bGH 20,000 HEK-293T
AAV6.CMV.LacZ.bGH 2,000 Huh7
AAV7.CMV.LacZ.bGH 5,000 HEK-293T
AAV8.CMV.LacZ.bGH 10,000 HEK-293T
AAV9.CMV.LacZ.bGH 10,000 HEK-293T
https://doi.org/10.1371/journal.pone.0212811.t001
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(100 μl) was added to each well and incubated at 37˚C for 30 minutes. The optical density
(OD) was measured at 405 nm on a SpectraMax Plus 384 Microplate Reader (Molecular
Devices, San Jose, USA). Samples that inhibited AAV transduction at a dilution of 1:20 were
further diluted and tested at 1:40, 1:80, 1:160 and 1:320. The NAb titer was reported as the
highest dilution that inhibited AAV.CMV.LacZ transduction by�50% compared to the non-
serum control (as described by Calcedo et al., 2009). The limit of detection for the NAb assay
was 1:10 serum or plasma dilution.
Statistics
Statistical analyses were performed using GraphPad Prism for Windows, Version 5.03 (Graph-
Pad Software, San Diego, CA, USA). Differences between two groups were tested for signifi-
cance using the non-parametric Mann–Whitney U test for unpaired samples (pMW).
Frequencies were compared using Fisher’s exact test for small numbers (pF) and the chi2 test
(pChi2) otherwise. A p-value less than 0.05 was considered significant.
The linkage in seroreactivity between two different serotypes within one individual in the
client-owned cats was determined according to Calcedo and colleagues [17]. In brief, the
seroreactivity linkage ratio was calculated by dividing the prevalence of serotype A in the sub-
populations of cats that were positive for serotype B by the prevalence of serotype A in the sub-
populations of cats that were negative for serotype B. This seroreactivity linkage ratio between
the two serotypes A and B (denoted by RAB) with a particular threshold for positivity was cal-
culated with the formula [PAB+ × NB]/[PB × PAB-]. PAB+ denotes the number of samples posi-
tive for both serotypes (A and B). NB denotes the number of serum samples negative for
serotype B. PB denotes the number of samples positive for serotype B and PAB- denotes the
number of samples positive for serotype A and negative for serotype B. A ratio >1 suggests a
positive linkage (i.e., seroreactivity to one virus is associated with an increased frequency of
seroreactivity to another virus), whereas a ratio <1 indicates a negative association (i.e., seror-
eactivity to one virus reduces reactivity to a second virus) [17].
The maps were created using Quantum Geographic Information system (QGIS), Version
3.2.0.
Results
Sample characteristics of client-owned cats
In this study, samples from 230 cats from all over Switzerland were included. Of these cats,
47% were specified male (n = 109), 40% were specified female (n = 92) and 13% were of
unspecified sex (n = 29). The majority of the client-owned cats were European Shorthairs
(54%, n = 125); some cats were Birmans (3%; n = 8), British Shorthairs (3%, n = 7) or other
breeds, such as Siamese, Bengals, Maine Coons, Ocicats, and others (18%; n = 41); for 21%
(n = 49) of the cats, no information on breed was available. The ages of the cats ranged from 6
weeks to 21 years (median age = 9.5 years), and 3% were of unspecified age (n = 8).
Seroprevalence of AAV NAb in client-owned cats
Samples from the 230 client-owned cats and 20 SPF cats were analyzed for the presence of
NAb against AAV1, AAV2, AAV5, AAV6, AAV7, AAV8 and AAV9. NAb titers from all cli-
ent-owned cats are summarized in Fig 1; the geographic origin of the samples with NAb is
depicted in Fig 2 and listed in S1 and S2 Tables categorized into the different cantons and
regions. Overall, 122 client-owned cats showed positive neutralizing activity (53%), while in
108 cats no NAb were detected against any of the tested AAV serotypes (47%). The majority of
Pre-existing antibodies to gene therapy vectors in cats
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the client-owned cats with neutralizing activity (75 of 122 cats; 61%) had NAb against more
than one of the tested AAV serotypes: 38 cats had NAb against two serotypes, 25 cats against
three serotypes, seven cats against four serotypes, four cats against five serotypes and one cat
against all seven AAV serotypes investigated.
There were significant differences in the prevalence of NAb against the various AAV sero-
types (pChi2 < 0.0001; Fig 1). When titers�1:10 were included, NAb against AAV6 were the
least common (5%) and NAb against AAV7 were the most common (28%). NAb against
AAV1, AAV5 and AAV6 were significantly less prevalent than NAb against AAV7, AAV8 or
AAV9 (pF < 0.0001). The prevalence of NAb against AAV2 was intermediate, at 17%. When
only titers�1:20 or�1:40 were analyzed, the general NAb distribution remained similar to
what was found when all titers�1:10 were included (Fig 1). Again, high NAb titers against
AAV7, AAV8 and AAV9 were significantly more frequently found than NAb to AAV1, AAV5
or AAV6 (pF < 0.0001). The highest NAb titers were found against AAV7 (�1:160), while
AAV5 and AAV6 reached titers of only�1:20 (Fig 1).
Significant geographic differences among the different cantons of Switzerland were found
for the presence of NAb against AAV2, AAV7 and AAV9 (pChi2 < 0.0001 for AAV2 and
AAV7; pChi2 < 0.0039 for AAV9; Fig 2). In particular, the cantons of Unterwalden, Zug and
Appenzell showed high prevalence (e.g., 70%, 60%, and 60%, respectively, for AAV7), whereas
in the cantons of Zurich, Bern and Lucerne, rather low prevalence was found (e.g., 0%, 10%,
and 20%, respectively, for AAV7; S1 Table).
Age, breed and sex of the client-owned cats and presence of NAb against
AAV
When titers�1:10 were considered, the age of the cats with NAb to AAVs was not significantly
different from the age of the cats without detectable NAb to AAVs; this was true for NAb
against each AAV serotype as well as the combined AAV serotypes (S1 Fig). At higher titers,
significant differences were found for NAb against AAV2 (titers�1:20, pMW = 0.0350 [S1J
Fig] and�1:40, pMW = 0.0140 [S1R Fig]) and AAV7 (titers�1:40, pMW = 0.0194 [S1S Fig];
�1:80, pMW = 0.0354 and�1:160, pMW = 0.0121 [S1W and S1AA Fig, respectively]), where
cats with NAb were significantly younger than cats with low or no titers.
No significant difference in the presence of NAb to AAV serotypes (titers�1:10,�1:20 and
�1:40) could be detected between purebred cats (all breeds combined) and non-purebred cats
Fig 1. Prevalence of pre-existing NAb against AAV serotypes in client-owned domestic cats from Switzerland
depicted according to titers. The percentage of NAb against different AAV serotypes is shown for serum dilutions of
�1:10;�1:20,�1:40,�1:80 and�1:160. NAb against AAV7, AAV8 and AAV9 were the most prevalent; NAb against
AAV1, AAV5 and AAV6 were the least prevalent.
https://doi.org/10.1371/journal.pone.0212811.g001
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Fig 2. Geographic origin of cats with NAb against AAV in Switzerland. NAb against A) AAV1, B) AAV2, C) AAV5, D) AAV6, E)
AAV7, F) AAV8, and G) AAV9 are shown. Dots represent samples with positive NAb against an AAV serotype. Higher color intensity
Pre-existing antibodies to gene therapy vectors in cats
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(European Shorthairs and mixed-breeds); again, this was true for NAb against each of the
tested AAV serotypes (S2 Fig), with the exception of NAb titers�1:40 against AAV2 (pF =
0.0038; S2R Fig) and�1:160 against AAV7 (pF = 0.0115, S2AK Fig). In these cases, purebred
cats had a significantly higher NAb frequency than non-purebred cats.
Moreover, there was no significant difference in the prevalence of NAb to AAV between
male and female cats (�1:10,�1:20,�1:40,�1:80 and�1:160) when NAb against each sero-
type were analyzed separately (S3 Fig). However, when NAb to all AAV were analyzed
together, female cats had a significantly higher frequency of NAb titers�1:40 than male cats
had (pF = 0.0046; S3X Fig).
Seroreactivity linkage analyses
To evaluate whether there was a linkage in the presence of NAb against two different AAVs
within one individual, a seroreactivity linkage analysis was performed. Most of the compari-
sons showed modest, as defined by Calcedo and colleagues [[17]; ratios: 1.8–3.0] or no correla-
tions (Table 2). Ratios higher than 3 were found between various AAV serotypes (Table 2).
The strongest positive correlation was observed between AAV6 and AAV8 (ratio 13.0).
Seroprevalence of AAV NAb in SPF cats
SPF cats showed no antibodies to AAVs with the exception of one cat [35], which had NAb
against AAV2 and AAV7 with a titer of�1:10. Thus, in SPF cats, the 5% prevalence of NAb
against AAV2 and AAV7 is lower than the prevalence of such NAb in client-owned cats,
which measured 17% and 28%, respectively (not significant for AAV2, pF = 0.2131, but statisti-
cally significant for AAV7, pF = 0.0305).
Discussion
The present study focused on investigating NAb against seven different AAV serotypes in the
domestic cat population of Switzerland. This is the first study to use an in vitro transduction
inhibition assay to test for biologically active NAb to AAVs in cats, as well as the first investiga-
tion of AAV seroprevalence in a large number of cats (n = 250). There has been only one
refers to higher positive NAb titers, with 1:160 being the darkest. Black dots represent geographic locations where more than one sample
with a positive NAb was found. In this case, all positive samples are clustered around the black dot.
https://doi.org/10.1371/journal.pone.0212811.g002
Table 2. Linkage of seroreactivity (RAB) between AAV serotypes in client-owned cats in Switzerland (NAb titer: 1:10).
Seroreactivity linkage ratio (RAB)
AAV1 AAV2 AAV5 AAV6 AAV7 AAV8 AAV9
AAV1 NA 1.2 0.9 7.2 1.3 2.5 1.0
AAV2 1.2 NA 2.3 1.6 3.9 2.1 2.9
AAV5 0.9 2.6 NA 1.2 3.7 4.1 2.7
AAV6 8.2 1.8 1.3 NA 1.0 13.0 2.2
AAV7 1.2 2.9 2.3 1.0 NA 2.4 3.4
AAV8 1.9 1.9 2.6 3.6 2.5 NA 2.5
AAV9 1.0 2.7 2.2 1.9 4.6 2.8 NA
NA: Not applicable. A ratio of >1 suggests a positive linkage (i.e., presence of NAb to one AAV is associated with an increased frequency of seroreactivity to another
AAV); a ratio <1 indicates a negative association. Bold numbers represent linkage ratios >3. More details on the calculations can be found in Materials and Methods.
https://doi.org/10.1371/journal.pone.0212811.t002
Pre-existing antibodies to gene therapy vectors in cats
PLOS ONE | https://doi.org/10.1371/journal.pone.0212811 March 21, 2019 8 / 19
previous study on the subject in cats; that study was smaller and examined total antibodies to
AAVs in cats using an ELISA technique [36].
In numerous studies cats are serving as animal models for human diseases, examples
include AIDS, diabetes, cancer and Alzheimer’s disease [24, 37–39]. Cats are, in contrast to
laboratory mice, an outbred species, have a longer lifespan, are bigger and show many mono-
genetic disorders like humans. Thus, studies in cats using gene therapy to treat diseases, such
as the mucopolysaccharidosis type VI (MPS VI), have great potential. Treated cats showed
long-term improvements including clearance of glycosaminoglycans, reduction of heart valve
thickness, improvement of long bone length and spontaneous mobility [40]. However, one
study showed that pre-existing immunity even at low levels (1:5/1:10 to undetectable) had a
negative impact on AAV8-mediated liver gene transfer in MPS VI cats, severely limiting thera-
peutic efficacy [30].
Gene therapy has also been suggested in domestic cats, e.g. to permanently sterilize the ani-
mals for population control and to avoid euthanasia of healthy adult cats [36]. Based on esti-
mations, there are approximately 1.6 million cats living in Switzerland in 2018 (https://de.
statista.com). Of these cats, approximately 100,000–300,000 cats were stray cats (http://www.
shkr.ch). Worldwide, estimates of cat numbers are around 600 million (http://www.ecology.
com), including a significant number of stray cats. Thus, the benefit of a one-time gene therapy
in comparison with a surgery in potentially millions of cats worldwide would be substantial.
An environment matched cat population would significantly improve animal welfare as well
as reduce the cat’s effect on the ecological balance (potential threat to reptiles, birds and small
mammals) and their potential role in serving as vectors for human diseases [41].Thus, an inex-
pensive, simple method to induce permanent infertility leading to a stable cat population is
highly desirable.
In the last few decades, several methods have been developed to detect antibodies against
AAV. In the 1970s, measurements of total antibodies to AAV1 and AAV2 –the available sero-
types at the time–were performed by ELISA and Western blot [42]. In order to determine sero-
type-specific NAb and not only binding Ab, in vitro transduction inhibition assays and in vivo
methods were developed. The in vivo assay uses mice, which are injected with the test serum
sample prior to vector delivery [43, 44]. The vector expresses a secreted reporter gene whose
expression is compared to the level in control mice injected with only the AAV vector. This
assay is highly sensitive; however, it is also time consuming, more expensive than in vitro
methods and reliant on animal experiments, which goes against the 3Rs principle for animal
welfare. In contrast, the in vitro transduction inhibition assay measures a reporter gene after
transduction with an AAV vector preincubated with the test serum [17, 45, 46]. Thus, this
Table 3. Overview of the prevalence (in %) of NAb to AAV in various animal species.
AAV1 AAV2 AAV5 AAV6 AAV7 AAV8 AAV9
Piga� 47 30 100 6 NA 35 NA
Catb 7 17 7 5 28 26 20
Doga 100 0 0 100 NA 0 NA
Horsea� 0 8 100 8 NA 0 NA
Nonhuman primatec 17� �100 �100 �100�
a[48]
bpresent study
c[53, 54]
� small number of animals in the study, n < 20.
https://doi.org/10.1371/journal.pone.0212811.t003
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assay does not involve experimental animals, has a high throughput capacity, and is shown to
have a good correlation with in vivo transduction in macaques (Calcedo and Wilson 2013).
Therefore, the in vitro transduction inhibition assay for the determination of NAb to AAVs is
currently the most widely used method to evaluate clinical samples.
Initially, it was assumed that only nonhuman primates and humans have pre-existing NAb
against AAV, since no NAb to AAV were detected in rats [47]. Subsequently, however, NAb to
AAV were detected in other mammalian species, such as the mouse, rabbit, dog and pig (see
Table 3 for an overview) [33, 48]. It became evident that the prevalence of NAb depends on
both the AAV serotype and the host species [33, 48]. In the present study, NAb to seven AAV
serotypes were determined in the Swiss cat population. However, it needs to be mentioned
that at present we do not know whether NAb detected in cats against the various rAAVs were
raised against human AAVs or are cross-reactive NAb to feline wild-type AAVs. Both explana-
tions should be considered: Close contact with humans, where AAV infections appear to be
endemic, could result in cross-species infection, leading to cats showing NAb against specific
human AAV serotypes. Transmission between hosts has been suggested based on the phyloge-
netic relationship of AAV isolates between humans and non-human primates [49], as well as
humans and ruminants [50]. In addition, it has been shown that pigs obtained from privately
owned farms were more frequently AAV infected than pigs from slaughterhouses [51]. This
could suggest that close contact of farmed pigs to humans provides an environment for zoo-
notic transmission. Thus, the close contact between cats and humans might lead to cats show-
ing NAb against specific human AAV serotypes. Alternatively, previous infection with a
potential feline wild-type AAV should to be considered as source of cross-reactive NAb against
human AAVs.Indeed, using an AAV2-ITR specific qPCR assay [52], 54 Swiss field cats were
tested for the presence of AAV2. Four (7%) of these samples tested low positive for rAAV2 (Ct
values>36). Due to the high Ct values (low loads), no sequencing for confirmation of the PCR
results was possible. Thus, future investigations of the potential presence of feline or human
AAVs in domestic cats will be interesting.
NAb were detected against all seven serotypes, with the highest prevalence of NAb to
AAV7, AAV8 and AAV9 (20–28%). This prevalence is lower than what was reported in 35 cli-
ent-owned cats from the Animal Health Diagnostic Center of Cornell University (30–80%)
[36]. However, as mentioned above, not NAb but total anti-AAV-capsid antibodies were mea-
sured in that study, a fact that may readily explain the discrepancies in prevalence between the
two studies. Our results partially mirror the situation in nonhuman primates, including
macaques, squirrel monkeys, chimpanzees and baboons [53, 54], where AAV7, AAV8 and
AAV9 were also the serotypes with the highest prevalence of NAb. However, up to 100% of the
nonhuman primates were positive for NAb to AAV7, AAV8 and AAV9 [53, 54], while in our
study the NAb prevalence never reached 30% for any serotype tested (Table 3). In horses and
pigs, NAb to AAV5 were the most prevalent (100%); in dogs, NAb to AAV1 and AAV6 were
found in 100% of the samples tested [48, 55]; and in humans, NAb to AAV2 were found fre-
quently (30–72%) [17, 42, 45, 56].
Co-occurrence of NAb to another AAV serotype was found in 61% of cases in the present
study. Previous studies have determined an even higher co-prevalence of up to 91% in humans
[56].
Regarding neutralization titers, titers of up to 1:12,800 were found against AAV2 in humans
[56]. Generally, lower titers were detected in cats, with AAV7 having the highest NAb titers
(1:160), followed by AAV8 and AAV9 (1:80; Fig 1). Findings in horses showed the highest
titers for NAb to AAV5, with titers of up to 1:80 [48]; in dogs, to AAV1 and AAV6, with titers
of up to 1:640 and 1:1024, respectively [33, 48]; and in pigs, to AAV1, AAV2, AAV5 and
AAV8, with titers of up to 1:160 [33, 48]. Thus, titers as high as the ones described in humans
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have not been found in large animals. However, titers seem to vary substantially between dif-
ferent species. Overall, the prevalence of NAb to AAVs in the cat population investigated in
the current study were considerably lower than what has been reported from other species; on
the other hand, in one cat NAb were found against all the AAVs investigated and some cats
had NAb against several of the AAV serotypes.
The samples included in the present study were collected from cats during veterinary con-
sultation. Most of the cats, therefore, were probably clinically ill, or they were healthy and
being presented for vaccination, castration, or other procedures. Thus, our study gives the
prevalence of NAb to AAVs in cats presented to veterinarians. This population may at least
partially represent the cats that are candidates for a future gene therapy approach. The samples
investigated in this study were residual samples, collected in the clinics for unrelated reasons.
The available volume, which is usually quite limited for feline samples, defined the minimal
dilution investigated in the neutralization assay (which was 1:10). Dilutions of 1:2 or 1:5 were
not feasible. Earlier publications state that AAV8 NAb titers of 1:20 were enough to completely
block transduction in passively immunized mice [48] and that AAV8 NAb titers greater than
1:10 were enough to significantly reduce AAV8 transduction of the liver in monkeys [57].
Despite the rather small area of Switzerland, significant geographic differences in the preva-
lence of NAb were found among the distinct cantons. In particular, the cantons of Unterwal-
den, Zug and Appenzell showed high prevalence, whereas the cantons of Zurich, Bern and
Lucerne had rather low prevalence. Regional differences had already been described, with sig-
nificantly higher frequencies of NAbs to all AAV serotypes in humans from Africa than in
those from other continents [17], as well as differences in the prevalence of NAb against AAV1
in two separate regions of China [58]. Both studies stated that significantly higher NAb against
AAV were detected in developing than developed regions, and it was speculated that living
conditions, population density, hygienic conditions or MHC background could be involved in
this phenomenon [17, 58]. In fact, in the present study, cats from typical urban regions showed
the lowest NAb prevalence (Zurich, Bern and Lucerne), whereas cats from rural regions
(Unterwalden, Appenzell) revealed higher NAb prevalence. It might be speculated that,
indeed, cats from rural regions have more outdoor access and are more likely to live in multi-
cat households, resulting in more antigen exposure than typical urban cats. Interestingly, NAb
frequency against AAV2 was significantly higher in purebred cats than non-purebred cats
(titers�1:40 against AAV2; pF = 0.0038; S2R Fig). In contrast to non-purebred cats, purebred
cats might be more likely restricted to indoors and have closer contact to humans, where
AAV2 infections seem to be quite common. However, in order to solidify either hypothesis
more cats and additional information, such as outdoor access, etc., would need to be
investigated.
Although no significant link between the presence of NAb against single AAV serotypes
and the sex of the cat could be found, combined NAb to AAV at a titer of�1:40 showed signif-
icantly higher NAb prevalence in females than in males (pF = 0.0046; S3X Fig). Earlier studies
showed that the immune system is broadly affected by the sex of the animal [59, 60]. Intact
female cats showed a lower rate of apoptotic lymphocytes after overnight culture than castrated
cats, and estradiol protected peripheral lymphocytes from apoptosis after stimulation in female
cats [61]. B lymphocytes produce antibodies; if apoptosis of B lymphocytes is lower in female
than male cats, this may contribute to higher NAb in females. However, only information on
sex and not on castration status was available from the cats in the present study.
The linkage of seropositivity for distinct AAV serotypes was not prominent for the majority
of serotypes investigated (Table 2). Most seroreactivity ratios showed modest correlations, as
defined by Calcedo and colleagues ([17]; ratios: 1.8–3.0). The strongest correlation of seroreac-
tivity was observed between AAV6 and AAV8 (ratio of 13.0), meaning that most cats
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seropositive for AAV6 were also seropositive for AAV8. However, it must be noted that ratios
higher than the present ratio of 13.0 have been described for human samples, with values
>100 [17]. Previous publications from studies in humans suggest that cross-reactive antibodies
to AAV5 and AAV6 were generated after exposure to wild-type AAV2 [56]. In the present
study, such cross-reactivity of NAb to AAV2 and AAV5 or AAV6 was not observed. Due to
the high similarity of capsids of AAV1 and AAV6 in humans (99.2% homology, [62]), one
would expect a high linkage of seropositivity. Indeed, a rather strong linkage of seroreactivity
was also observed here with ratios of 7.23 and 8.19 (Table 2). Most serotypes investigated
showed absence of substantial linkage of seropositivity, which is in accordance with several
studies investigating repeated AAV administration in mice [63, 64]. In addition, it was shown
that the various AAV serotypes differ in their immunogenic potential. Thus, at present we can
only speculate whether the low levels of linkage of seropositivity are due to sequence variations
between human AAVs and potential feline AAVs and/or differences in the immunogenicity of
the AAVs and the immune reaction of the cat. It has been considered that co-occurrence of
NAb might be either the result of multiple infections or co-infections with several AAV within
the same individual [56].
As expected, most SPF cats did not have detectable levels of NAb, with the exception of one
cat, which had low titers of NAb against AAV2 and AAV7. This cat was infected with FeLV-A/
Glasgow-1 in an unrelated study [35] and had developed acute leukemia at the time of eutha-
nasia when the serum was collected for this study. In contrast to a study by Dissen and col-
leagues [36], where recently vaccinated SPF cats showed cross-reactive NAb against AAV6, the
SPF cats in the present study had never been vaccinated to the best of our knowledge. In agree-
ment with this, no antibodies were detected for parvo-, herpes-, or calicivirus in the serum of
the AAV NAb-positive cat (S3 Table and S1 File). Thus, it remains unclear at present how the
cat acquired the AAV NAb.
Several studies have shown that pre-existing NAb against AAV present a significant hurdle
for gene therapy [5, 13, 14]. In the Calcium Upregulation by Percutaneous Administration of
Gene Therapy in Cardiac Disease (CUPID) study, almost 50% of patients had to be excluded
from therapy due to NAb titers of>1:2 [19]. In the first hemophilia B clinical trial, NAb titers
of 1:17 completely blocked detectable levels of factor IX transgene expression, while another
subject with a titer of 1:2 developed only low levels of expression [5]. Thus, even low titers of
pre-existing NAb may significantly neutralize high doses of vector. However, although anti-
AAV immune responses can result in loss of transgene expression, it is primarily the efficiency
of the gene therapy and not its safety that is at stake [15]. Moreover, the presence of NAb
might not influence all gene therapy studies due to the route of administration or the large vec-
tor doses per kg body weight used. Interestingly, the presence of NAb against AAV does not
impede transduction when administered by the intraparenchymal route, into the subretinal
space [65] or into the cerebral ventricle [66]. Little to no capsid- or transgene-specific immune
response could be detected in serum or PBMCs after gene therapy to immune-privileged com-
partments of the body such as the eye or central nervous system [67]. Probably the immuno-
logic unresponsiveness of the brain and eye is dependent on the vector dose; thus, future
studies will define the upper limit for the vector dose [67].
Despite the broad usage of AAV vectors in clinical trials, pre-existing antibodies always
remain a barrier for the therapy efficacy. To solve this issue, an alternative strategy uses the
AAV hybrid strain AAV-DJ to escape NAb in vivo. This strain was derived from 8 wild sero-
types of AAV (AAV2, AAV4, AAV5, AAV8, AAV9, avian, bovine, caprine) by DNA family
shuffling technology [68]. During screening, the AAV-DJ strain was chosen as an immune-
escaping strain from the quasispecies library incubated with pools of polyclonal antibodies
against each AAV serotype. Since each wild serotype has its own tropism, the chimera
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inherited all the parental tropisms and showed almost equipotent infection efficiency through-
out the organs in mice [68]. In a preliminary experiment, we selected 20 samples of the current
study from client-owned domestic cats that had NAb against several AAV serotypes. The
majority of the samples (17/20) were not capable of neutralizing AAV-DJ (titer<1:10). The
exceptions were one sample with very broad neutralizing capacity (Uri #78), which had shown
NAb against all investigated serotypes, and two samples (Schwyz #83 and Glarus #114) that
had neutralized five or four of the seven investigated AAV serotypes, respectively (S4 Fig and
S1 File). Thus, these preliminary results indicate that in domestic cats, lower levels of pre-exist-
ing NAb to AAV-DJ can be expected compared to wild-type AAV serotypes. Future studies in
the cat may thus also concentrate on using AAV-DJ.
Conclusions
Compared with the prevalence of NAb against AAV in humans, the prevalence of NAb in cats
was reduced, ranging from 5%–28%. A low prevalence of NAb against AAV in cats supports
its applicability for gene therapy. However, due to the potential hindrance of NAb during gene
therapy and the currently rather high effort necessary for gene therapy, prescreening of the
individual animals for the presence of NAb to the AAV serotype in question may be advisable.
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